Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Shenshen Lai, Rick Li, Paromita Raha, Yuxiang Hu, Jun Yan, Hong Zhang, Anthony Marotta and Zaihui Zhang | ||||||||||||
Title | Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model | ||||||||||||
|
|||||||||||||
URL | https://mct.aacrjournals.org/content/17/1_Supplement/B148 | ||||||||||||
Abstract Text | Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SLC-391 | SLC391|SLC 391 | AXL Inhibitor 30 | SLC-391 is an Axl inhibitor that blocks the phosphotransferase activity of Axl, which potentially stimulates anti-tumor immune response and reverses immunosuppression leading to tumor growth inhibition (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|